Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 6, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

Hong Kong PhD Fellowship Scheme (HKPFS) 2021-2022

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses
  • BiotechToday
  • India
  • World

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

bioxone October 4, 2020October 4, 2020

Ayooshi Mitra, Amity University Kolkata

To avert the spread of the pandemic of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a successful vaccine is needed. In an examination directed recently, safety, tolerability, and neutralizer reaction information from an on-going placebo-controlled treatment observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial BNT162b1, a lipid nanoparticle (LNP) nucleoside-modified messenger RNA (mRNA) encoding the SARS-CoV-2 spike protein1 receptor-binding domain (RBD) was accounted for. Here, antibody and T-cell responses following BNT162b1 vaccination in a second, non-randomized, Phase 1/2 open-label trial in healthy adults aged 18-55 years were presented. 

Two dosages of 1 to 50 μg of BNT162b1 brought strong CD4 + and CD8 + T-cell and antibody responses, with RBD-binding IgG concentrations clearly above those in the COVID-19 sample (HCS) panel. For the 43rd day of SARS-CoV-2 serum neutralizing, mean values were 0.7-fold (1 μg) to 3.5-fold (50 μg) of the HCS panel. Immune sera broadly neutralized pseudoviruses with various SARS-CoV-2 spike variants. Most participants had positive T cell immune responses with CD8 + RBD-specific and CD4 + T-cell development. The tough RBD-specific antibody, T-cell, and favourable cytokine reactions induced by the BNT162b1 mRNA vaccine suggest multiple advantageous mechanisms with the potential to defend against the COVID-19.

References: Sahin, U., Muik, A., Derhovanessian, E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature (2020). https://doi.org/10.1038/s41586-020-2814-7 https://www.nature.com/articles/s41586-020-2814-7

Also read: Can high systemic inflammation biomarkers during puberty result in breast cancer?

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Antibody CORONAVIRUS COVID-19 cytokine reactions mRNA mRNA vaccine pandemic receptor binding SARS-CoV-2 successful vaccine T-cell and B-cell T-cell response VACCINE

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • India
  • World

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

bioxone October 4, 2020

Prama Ghosh, Amity University Kolkata 13 people from 8 states have been infected with the outbreak strain of Salmonella muenster linked to bearded dragons, as of 25th September, according to the latest information released from the Centers for Disease Control and Prevention (CDC).  Pet bearded dragons are likely the source of this outbreak as shown […]

Salmonella

Related Post

  • BiotechToday
  • World

BIOLOGICAL AGE AND ITS MANIPULATION!

bioxone November 16, 2020November 16, 2020

Aakancha Shaw, St. Xavier’s College, Kolkata The environment that an embryo encounters during its developing stage matters a lot because it has major consequences on the later-life of an individual.  Telomeres are the protective ends of chromosomes and their length is indicative of the “biological age” of an individual. Telomeres have a tendency to shorten […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

SGL: Hidden part in Bacteriophages could be a Protein Antibiotic

bioxone March 18, 2021March 18, 2021

Ayooshi Mitra, Amity University, Kolkata Antibiotic-resistant bacteria are becoming a greater threat to human health day by day, necessitating the development of new antibiotics. Bacteriophages and their potential as antibacterial agents to combat pathogenic bacteria have sparked renewed interest. This is largely due to the phage’s ability to cause a cellular breakdown in the bacterial […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Multiple Antibody Panel to treat Esophageal Squamous Cell Carcinoma (ESCC)

bioxone October 21, 2020October 21, 2020

Chitra Roy, University of Calcutta Cancer Immunotherapy work by helping the immune system to function in an efficient manner to fight cancer cells. For the immune system to start its response, it must first be able to identify and differentiate between self-part of your own body and non-self-foreign/antigen. Cancer Immunotherapy is generally divided in two […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy